Louise Provencher

Adjuvant Docetaxel for Node-Positive Breast Cancer

Miguel Martín, Tadeusz Pieńkowski, John R. Mackey et al. · New England Journal of Medicine · 2005 · 950 citations · Full text

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David Miles, Arlene Chan, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 881 citations

Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study

Jean-François Boileau, Brigitte Poirier, Mark Basik et al. · Journal of Clinical Oncology · 2014 · 816 citations

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Martine Piccart, Gabriel N. Hortobágyi, Mario Campone et al. · Annals of Oncology · 2014 · 554 citations · Full text

Breast Oncology, Oncology, Medicine +6

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer et al. · Journal of Clinical Oncology · 2019 · 406 citations · Full text